Search results
6 gru 2021 · Severe pneumonia is associated with high mortality (short and long term), as well as pulmonary and extrapulmonary complications. Appropriate diagnosis and early initiation of adequate antimicrobial treatment for severe pneumonia are crucial in improving survival among critically ill patients.
- Related Content
Severe pneumonia is associated with high mortality (short...
- Rapid Responses
Chętnie wyświetlilibyśmy opis, ale witryna, którą oglądasz,...
- Article Metrics
Severe pneumonia is associated with high mortality (short...
- Download
Chętnie wyświetlilibyśmy opis, ale witryna, którą oglądasz,...
- Related Content
5 sie 2016 · Over recent years, a better understanding of bacterial growth, metabolism, and virulence has offered several potential targets for developing therapeutics against bacterial pneumonia. This chapter will discuss the current and developing trends in treating bacterial pneumonia.
1 gru 2023 · The most frequently reported outcomes are treatment success (60.7%), mortality (56.4%) and adverse events (41.1%). • Our findings support the need for a rigorous core outcome set, such as that being developed by the European Respiratory Society.
31 paź 2023 · Diagnosis of pneumonia is based on symptoms and signs of an acute lower respiratory tract infection, and can be confirmed by a chest X-ray showing new shadowing that is not due to any other cause (such as pulmonary oedema or infarction).
29 cze 2020 · From empirical to targeted treatment on nosocomial pneumonia in ICU. After analyzing the onset, the previous use of antimicrobials or clinical condition (vHAP or VAP), empirical antimicrobial therapy is chosen based on risk factors, previous colonization, local flora and/or use of rapid techniques.
A recent trial (CAPE COD) among patients with severe community-acquired pneumonia in intensive care showed that hydrocortisone treatment resulted in 50% lower 28-day mortality, compared with placebo. 9 A large meta-analysis showed that the addition of corticosteroids was associated with a significantly lower mortality rate than placebo or usual ...
17 paź 2019 · To overcome this challenge, we need fast and accurate point-of-care testing to distinguish viral from bacterial pneumonia and elucidate the pathogen responsible for bacterial pneumonias, to allow targeted therapy and withdrawal of inappropriate treatment.
